Notably, the abovementioned biologic processes found to be mediated by fibroblasts-derived factors independently of KRAS highlight potential mechanisms of resistance to targeted therapies currently available for the treatment of CRC patients, such as anti-EGFR and anti-VEGF. This evidence concerns the gene KRAS and colorectal carcinoma.